Ascendis Pharma A/S (NASDAQ:ASND) announced its quarterly earnings results on Tuesday. The biotechnology company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.43) by $0.11, MarketWatch Earnings reports. Ascendis Pharma A/S had a negative net margin of 2,231.94% and a negative return on equity of 36.56%. The company had revenue of $2.45 million during the quarter, compared to analyst estimates of $2.66 million.
ASND opened at $146.84 on Friday. The stock’s fifty day simple moving average is $129.52 and its 200 day simple moving average is $126.37. Ascendis Pharma A/S has a 1-year low of $90.06 and a 1-year high of $150.00. The stock has a market cap of $7.02 billion, a PE ratio of -27.55 and a beta of 0.97. The company has a current ratio of 13.19, a quick ratio of 12.74 and a debt-to-equity ratio of 0.06.
A number of equities analysts recently weighed in on the stock. Bank of America reaffirmed a “buy” rating and issued a $145.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, March 27th. Credit Suisse Group upped their target price on shares of Ascendis Pharma A/S from $149.00 to $154.00 and gave the stock an “outperform” rating in a research note on Wednesday. Cantor Fitzgerald lifted their target price on Ascendis Pharma A/S from $185.00 to $201.00 and gave the company an “overweight” rating in a research report on Monday, April 20th. Oppenheimer cut their target price on Ascendis Pharma A/S from $219.00 to $208.00 and set an “outperform” rating on the stock in a research note on Wednesday. Finally, BidaskClub raised shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research note on Friday, May 8th. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $168.33.
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
Featured Article: What are the risks of holding treasury bonds?
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.